Results Wire: US FDA Advisory Committee Supports The Medicine Company’s Cangrelor, a Drug to Reduce CV Events in PCI Patients –April 15, 2015 (CRDAC)
On Wednesday, April 15, 2015 the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) supported, by a vote of 9-Yes to 2-No, with one abstention, the approval of cangrelor injection, submitted by The Medicines Company (MDCO). MDCO’s proposed indication is for the reduction of thrombotic cardiovascular (CV) events, including stent thrombosis in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.